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Abstract
Background: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®) and is
approved in Europe and elsewhere, mostly for the same indications as RP. The aim of this study was to compare
the 54-week efficacy, immunogenicity, pharmacokinetics (PK) and safety of CT-P13 with RP in patients with
ankylosing spondylitis (AS), with a focus on patient-reported outcomes (PROs).
Methods: This was a multinational, double-blind, parallel-group study in patients with active AS. Participants were
randomized (1:1) to receive CT-P13 (5 mg/kg) or RP (5 mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week
54. To assess responses, standardized assessment tools were used with an intention-to-treat analysis of observed
data. Anti-drug antibodies (ADAs), PK parameters, and safety outcomes were also assessed.
Results: Of 250 randomized patients (n = 125 per group), 210 (84.0 %) completed 54 weeks of treatment, with
similar completion rates between groups. At week 54, Assessment of Spondylo Arthritis international Society
(ASAS)20 response, ASAS40 response and ASAS partial remission were comparable between treatment groups.
Changes from baseline in PROs such as mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI;
CT-P13 −3.1 versus RP −2.8), Bath Ankylosing Spondylitis Functional Index (BASFI; −2.9 versus –2.7), and Short
Form Health Survey (SF-36) scores (9.26 versus 10.13 for physical component summary; 7.30 versus 6.54 for mental
component summary) were similar between treatment groups. At 54 weeks, 19.5 % and 23.0 % of patients
receiving CT-P13 and RP, respectively, had ADAs. All observed PK parameters of CT-P13 and RP, including maximum
and minimum serum concentrations, were similar through 54 weeks. The influence of ADAs on PK was similar in
the two treatment groups. Most adverse events were mild or moderate in severity. There was no notable
difference between treatment groups in the incidence of adverse events, serious adverse events, infections and
infusion-related reactions.
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Conclusions: CT-P13 and RP have highly comparable efficacy (including PROs) and PK up to week 54. Over a 1-year
period, CT-P13 was well tolerated and displayed a safety profile comparable to RP; no differences in
immunogenicity were observed.
Trial registration: ClinicalTrials.gov identifier: NCT01220518. Registered 4 October 2010.
Keywords: Biosimilar, CT-P13, Infliximab, Ankylosing spondylitis, Efficacy, Immunogenicity, Pharmacokinetics, Safety,
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Background
Infliximab is a human-murine chimeric monoclonal anti-
body directed against tumor necrosis factor (TNF). Ori-
ginator infliximab (Remicade®; hereafter referred to as the
reference product (RP)) was the first TNF antagonist
proven to be efficacious in patients with ankylosing spon-
dylitis (AS) [1, 2], and is now regarded as an important
component of AS care [3, 4]. However, the costs of inflixi-
mab RP and other originator biologics are often high, pla-
cing considerable financial burden on healthcare systems
and, in many countries, restricting patient access [5, 6]. As
a result, the development of biosimilar drugs has garnered
considerable interest as many originator biologics have
reached or are close to patent expiry. A biosimilar may be
defined as ‘a biotherapeutic product that is similar in
terms of quality, safety and efficacy to an already licensed
reference biotherapeutic product’ [7]. Due to their as-
sumed lower price, biosimilars have the potential to re-
duce costs and increase patient access and drug therapy
adherence.
CT-P13 (Remsima®, Inflectra®) is a biosimilar of RP
produced in the same murine hybridoma cell line as RP
and approved in Europe and elsewhere for the same in-
dications. CT-P13 and RP are identical in amino acid se-
quence, pharmaceutical form, strength, composition,
and route of administration [8, 9]. Secondary and ter-
tiary structures of CT-P13 and RP are highly comparable
to each other, although not identical. Both drugs bind to
known infliximab ligands and receptors (e.g., TNF, Fcγ
and C1q) with similar affinity, while neither bind to lym-
photoxin. In vitro studies have shown that CT-P13 and
RP possess equivalent TNF neutralization activity, apop-
totic activity, complement-dependent cytotoxicity and
antibody-dependent cellular toxicity [8, 9].
Biosimilar guidelines in Europe and the US state that
demonstration of clinical comparability between a biosimi-
lar and its innovator requires completion of comparator
clinical trials assessing pharmacokinetics (PK), efficacy and
safety [10, 11]. Efficacy equivalence of CT-P13 and RP was
established in the PLANETRA (Programme evaLuating
the Autoimmune disease iNvEstigational drug cT-p13 in
Rheumatoid Arthritis) study [12]. Another study called
PLANETAS (Programme evaLuating the Autoimmune
disease iNvEstigational drug cT-p13 in AS patients) was
conducted to assess PK equivalence and comparability of
efficacy and safety in patients with AS. The primary ana-
lysis of PLANETAS was performed at week 30 of the
study [13]. That analysis showed that the primary end-
point of the study—PK equivalence of CT-P13 and RP as
assessed by steady state area under the serum concentra-
tion curve (AUC) and maximum serum concentration
(Cmax) between weeks 22 and 30—was met. Efficacy and
safety findings up to week 30 were also similar in the pa-
tients with AS.
In order to compare the extended efficacy, immuno-
genicity, PK and safety of CT-P13 and RP in patients
with AS, PLANETAS continued up to 54 weeks (plus a
subsequent off-dose period of 8 weeks). Here, we report
the results of the study at week 54.
Methods
Study methods have been reported in detail previously [13].
Patients
AS patients aged 18–75 years meeting the 1984 modified
New York classification criteria [14] for ≥3 months prior
to screening, with Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) score of ≥4 (range 0–10) and a
visual analogue scale score for spinal pain of ≥4 (range
0–10) were eligible for the PLANETAS study. Patients
were permitted to receive both oral glucocorticoids
(equivalent to ≤10 mg daily prednisolone) and nonsteroi-
dal anti-inflammatory drugs, if they had received a stable
dose for ≥4 weeks prior to screening.
Study design and treatment
This randomized, double-blind, parallel-group study
(ClinicalTrials.gov identifier: NCT01220518) was conducted
in 46 centers in 10 countries. Patients were randomly
assigned in a 1:1 ratio to receive CT-P13 (CELLTRION Inc,
Incheon, Republic of Korea) or RP (Janssen Biotech Inc,
Horsham, Pennsylvania, USA), at a dose of 5 mg/kg via 2-
hour intravenous infusion at weeks 0, 2 and 6, and then
every 8 weeks thereafter up to week 54. Antihistamines
were provided prior to infusion at the investigator’s discre-
tion. The overall randomization code was broken for regu-
latory reporting purposes once the database up to week 30
had been finalized for analysis [13]. However, the study
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remained blinded to the investigators and patients up to
week 54.
The study was carried out according to the principles
of the Declaration of Helsinki and International Confer-
ence on Harmonisation good clinical practice guidelines.
The study was approved by the relevant independent
ethics committees (see Acknowledgements). All patients
provided written informed consent.
Study endpoints and assessments
Efficacy was assessed at baseline and weeks 14, 30 and 54.
Efficacy endpoints included: patient-reported outcomes
(PROs), including BASDAI, the Bath Ankylosing Spondyl-
itis Functional Index (BASFI), and the Short Form (36)
Health Survey (SF-36); the proportion of patients achiev-
ing clinical response according to Assessment of Spondy-
loarthritis international Society (ASAS)20 and ASAS40
criteria; the proportion of patients with ASAS partial re-
mission; changes from baseline in Ankylosing Spondylitis
Disease Activity Score (ASDAS)-C-reactive protein (CRP),
Bath Ankylosing Spondylitis Metrology Index (BASMI)
and chest expansion.
The proportion of patients who tested positive for
anti-drug antibodies (ADAs) was assessed at baseline
and weeks 14, 30 and 54 using an electrochemilumines-
cent immunoassay method, as previously reported [13].
The neutralizing activity of ADAs was also assessed by a
flow-through immunoassay method utilizing the Gyros
Immunoassay platform (Gyros AB, Sweden). Primary PK
endpoints included the area under the concentration
time curve over the dosing interval, at steady state be-
tween week 22 and week 30 (AUCτ) and the observed
maximum serum concentration at steady state between
week 22 and week 30 (Cmax,ss). Secondary assessments
included Cmax and minimum concentration (Cmin) im-
mediately before the next infusion up to week 54. Blood
samples were collected immediately before each treatment,
at the end of each infusion, and 60 minutes post-infusion.
PK analyses were performed using a flow-through im-
munoassay platform (Gyros AB, Sweden). The influence of
ADA titer level on primary PK endpoints was assessed
with a low, medium and high ADA titer based on tertile
grouping of the data.
Regarding safety, adverse events (AEs) were assessed
from enrollment and up to 8 weeks after last study treat-
ment. A treatment-emergent AE (TEAE) was defined as
any event not present before exposure to study treat-
ment or an event that worsened in intensity or fre-
quency after exposure to study treatment. Other safety
assessments included vital signs monitoring, physical
examination, clinical laboratory analyses, and tubercu-
losis (TB) monitoring. An AE of latent TB was reported
if a patient had a positive result on interferon-γ release
assay after a negative result at baseline together with a
negative result on chest X-ray examination. Patients
were monitored for infusion-related reactions, including
hypersensitivity and anaphylactic reaction.
In a series of subgroup analyses, the impact of ADA sta-
tus on efficacy, PK and safety was determined. For subana-
lysis of ASAS20 response, ADA status was determined at
week 54. For Cmax subanalysis, a non-visit-based approach
was adopted to evaluate the incidence of patients who
developed ADAs up to and including week 54. In sub-
group analysis of infusion-related reactions, patients were
grouped according to their seroconversion status, which
was defined as positive if the patient had a negative ADA
test followed by a positive ADA test at a subsequent visit;
all other patients who provided at least one ADA test re-
sult were included in the non-seroconverted group.
Statistical analyses
Statistical analyses were performed using Version 9.1.3 of
SAS software (SAS Institute, Inc, Cary, North Carolina,
USA). All efficacy analyses were performed by intention-to-
treat, using the ‘missing equals excluded’ (MEX) approach.
The proportion of patients achieving clinical response
(ASAS20/ASAS40) was analyzed by a logistic regression
model, with treatment group as a fixed effect and the strati-
fication factors (region and baseline BASDAI score) as co-
variates. Treatment effect was estimated by calculating the
odds ratio (OR) and 95 % confidence interval (CI). Other
efficacy endpoints were analyzed using descriptive statistics.
For PK analyses, serum drug concentrations were
summarized using quantitative descriptive statistics by
actual treatment group, visit and time point. The PK
population included patients who received at least the
first five doses of study treatment, had sufficient blood
concentration data to facilitate the calculation of PK pa-
rameters, and had no major protocol deviations. The
safety population included all patients who received at
least one (full or partial) dose of CT-P13 or RP during
any dosing period.
Sensitivity analyses of ASAS response data were con-
ducted using a last observation carried forward (LOCF)
approach to compare the full-set analysis (LOCF) with
the complete-case analysis (MEX).
Results
Patient disposition and baseline characteristics
Overall, 250 patients were randomly assigned to study
treatment (n = 125 in each group; Fig. 1). A total of 210
patients completed 54 weeks of treatment (n = 106
(84.8 %) and 104 (83.2 %) in the CT-P13 and RP groups,
respectively). The most common reason for discontinu-
ation was AEs (n = 13 (10.4 %) and 10 (8.0 %), respect-
ively) in each group.
Baseline patient demographics and disease characteris-
tics are shown in Table 1. In both the CT-P13 and RP
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groups the majority of patients were male (n = 99
(79.2 %) and n = 103 (82.4 %), respectively), and median
age was 38 years in both groups (range 18–69 years).
Baseline scores for efficacy assessments, including PROs,
were similar between groups.
Efficacy
Efficacy was similar between both treatment groups, as
measured by all efficacy endpoints. The proportion of
patients achieving clinical response according to
ASAS20 and ASAS40 criteria at weeks 14, 30 and 54
was similar between the CT-P13 and RP groups, as were
ASAS partial remission rates (Fig. 2a). Logistic regres-
sion indicated no difference in ASAS20 responses be-
tween CT-P13 and RP at week 54 (0.89 (0.50, 1.59)).
Similarly, there was no difference between CT-P13 and
RP for ASAS40 responses at week 54 (1.26 (0.73, 2.15)).
Sensitivity analyses of ASAS response rates using the
full-set (LOCF) population also showed no differences
between CT-P13 and RP (Fig. 2b). In a subgroup analysis
performed according to ADA status, the proportion of
ADA-negative patients achieving ASAS20 at week 54
was 72.3 % in the CT-P13 group and 73.1 % in the RP
group. In comparison, 47.8 % and 60.0 % of ADA-
positive patients in the CT-P13 and RP groups, respect-
ively, achieved ASAS20 at week 54.
ASDAS-CRP score (mean ± standard deviation (SD))
at baseline (3.8 ± 0.8 and 3.9 ± 1.1 in the CT-P13 and RP
groups, respectively) and the mean change from baseline
were similar in the CT-P13 and RP groups at week 54
(−1.7 ± 1.3 and −1.7 ± 1.3).
In terms of PROs, baseline scores of BASDAI and
BASFI were similar between groups, and the scores
decreased from baseline up to week 54 to a similar ex-
tent in both the CT-P13 and RP groups (mean ± SD
BASDAI scores at baseline: 6.7 ± 1.4 versus 6.6 ± 1.6 in
the CT-P13 and RP groups, respectively; change from
baseline BASDAI scores: −2.9 ± 2.2 versus −2.8 ± 2.1 (week
14), −3.0 ± 2.2 versus −2.7 ± 2.2 (week 30) and −3.1 ± 2.3
versus −2.8 ± 2.2 (week 54); BASFI scores at baseline:
6.2 ± 1.9 versus 6.2 ± 2.2; change from baseline BASFI
scores: −2.5 ± 2.1 versus −2.5 ± 2.2 (week 14), −2.6 ± 2.2
versus −2.5 ± 2.2 (week 30) and −2.9 ± 2.3 versus −2.7 ±
2.1 (week 54)) (Fig. 3a and b). Regarding the SF-36 quality
of life questionnaire, scores were similar between CT-P13
and RP groups for all components of the questionnaire at
baseline and weeks 14, 30 and 54. Mean SF-36 score in-
creased from baseline to week 54 in both groups. For the
physical component summary (Fig. 3c), the mean ± SD
scores at baseline were 33.4 ± 6.7 and 32.2 ± 6.8, and at
week 54 were 42.4 ± 8.6 and 42.2 ± 9.0 with CT-P13 and
RP, respectively. For the mental component summary
(Fig. 3d), the mean scores at baseline were 38.1 ± 10.3 and
37.5 ± 11.2, and at week 54 were 44.9 ± 10.9 and 44.9 ±
11.0 with CT-P13 and RP, respectively. In the CT-P13 and
RP groups, respectively, mean change from baseline to
week 54 was 9.26 and 10.13 for the physical component
summary and 7.30 and 6.54 for the mental component
summary.
Mean ± SD BASMI scores and chest expansion (cm) at
baseline were 4.0 ± 2.1 versus 4.1 ± 2.1, and 3.2 ± 1.3 ver-
sus 2.9 ± 1.3 in the CT-P13 and RP groups, respectively.
Mean change from baseline values were similar in the CT-
P13 and RP groups (week 14: −0.7 ± 1.2 versus −0.7 ± 1.4;
week 30: −1.0 ± 1.4 versus −0.9 ± 1.4; week 54: −1.1 ± 1.5
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Fig. 1 Flowchart of patient disposition. A total of 250 eligible patients were randomized into the CT-P13 group (n = 125) or RP group (n = 125) to
receive 5 mg/kg of CT-P13 or RP, respectively. All 250 randomly assigned patients were included in the intention-to-treat population. *One patient
randomly assigned to RP received at least one dose of CT-P13 unintentionally. RP reference product (i.e., reference infliximab)
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versus 0.7 ± 1.0; week 30: 0.6 ± 1.4 versus 0.8 ± 1.2; week
54: 0.7 ± 1.4 versus 0.9 ± 1.1 for chest expansion).
Immunogenicity
The proportion of patients with ADAs was similar be-
tween the CT-P13 and RP groups at each time point
(week 14: n = 11 (8.6 %) and n = 13 (10.7 %); week 30: n =
32 (25.0 %) and n = 25 (20.5 %); week 54: n = 25 (19.5 %)
and n = 28 (23.0 %)). The vast majority of patients who
were ADA-positive also had neutralizing activity in both
the CT-13 and RP groups (week 14: n = 10 and n = 13;
week 30: n = 31 and n = 24; week 54: n = 25 and n = 28).
Pharmacokinetics
A total of 223 (89.2 %) patients were included in the PK
population (n = 113 and n = 110 in the CT-P13 and RP
groups, respectively). Cmax and Cmin values were similar
between the two treatment groups up to week 54
(Fig. 4).
The influence of ADAs on primary PK endpoints
(Cmax,ss and AUCτ) was also investigated. Figure 5 shows
these endpoints by ADA titer level at week 30 in the
CT-P13 and RP groups. There was a trend for both
Cmax,ss and AUCτ to be lower with higher ADA titer
levels. This impact of ADAs on drug exposure was simi-
lar in the two treatment groups. In a related subgroup
analysis, mean (coefficient of variation) Cmax was com-
parable in the CT-P13 and RP groups at week 54 in both
ADA-negative (142.98 (27.6) versus 135.27 (22.6) μg/mL,
respectively) and ADA-positive (122.53 (31.1) versus
117.16 (25.6) μg/mL) patients.
Safety
Due to incorrect kits being dispensed, three patients
randomly assigned to the RP treatment group received
one dose of CT-P13 in this study. Therefore, the safety
population comprised 128 and 122 patients in the CT-
P13 and RP groups, respectively.
Table 1 Baseline patient demographics and disease characteristics
Characteristic CT-P13 RP Total (n = 250)
5 mg/kg (n = 125) 5 mg/kg (n = 125)
Age, years 38.0 (18–69) 38.0 (18–66) 38.0 (18–69)
Gender, no. (%)
Male 99 (79.2) 103 (82.4) 202 (80.8)
Female 26 (20.8) 22 (17.6) 48 (19.2)
Ethnicity, no. (%)
Caucasian 97 (77.6) 92 (73.6) 189 (75.6)
Asian 16 (12.8) 13 (10.4) 29 (11.6)
Other 12 (9.6) 20 (16.0) 32 (12.8)
Height, cm 172.0 (148–198) 171.0 (147–193) 172.0 (147–198)
Weight, kg 72.70 (45.0–120.0) 76.00 (45.5–122.7) 73.75 (45.0–122.7)
Body mass index, kg/m2 24.39 (18.0–38.7) 25.64 (17.5–42.0) 25.12 (17.5–42.0)
ASDAS-CRP, mean ± SD 3.8 ± 0.8 3.9 ± 1.1 3.9 ± 1.0
BASDAI (stratification factor), no. (%)
4 ~≤8 92 (73.6) 95 (76.0) 187 (74.8)
>8–10 33 (26.4) 30 (24.0) 63 (25.2)
BASDAI score 6.8 (3.4–10.0) 6.6 (1.8–10.0) 6.7 (1.8–10.0)
BASFI score 6.3 (0.7–9.8) 6.3 (0.1–10.0) 6.3 (0.1–10.0)
BASMI score 4.0 (0.0–9.0) 4.0 (0.0–9.0) 4.0 (0.0–9.0)
Chest expansion, cm 3.0 (0.5–9.0) 2.5 (0.0–7.0) 3.0 (0.0–9.0)
SF-36 summary scores
Physical component 34.1 (16.2–49.7) 33.1 (15.3–54.3) 33.4 (15.3–54.3)
Mental component 38.2 (15.1–63.7) 37.2 (12.5–63.6) 37.8 (12.5–63.7)
CRP, mg/dL 1.1 (0.0–13.0) 1.4 (0.0–17.4) 1.3 (0.0–17.4)
ESR, mm/h 33.0 (2.0–110.0) 34.0 (1.0–119.0) 34.0 (1.0–119.0)
Except where indicated otherwise, values are expressed as median (minimum–maximum). ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing
Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein,
ESR erythrocyte sedimentation rate, RP reference product (i.e. reference infliximab), SD standard deviation, SF-36 Short Form (36) Health Survey
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The proportion of patients who experienced at least
one TEAE was similar in the CT-P13 and RP groups
(n = 95 (74.2 %) and 82 (67.2 %), respectively). Most
TEAEs were mild or moderate in intensity. TEAEs consid-
ered by the investigator to be related to study treatment
were reported in 64 (50.0 %) and 63 (51.6 %) patients, re-
spectively. The most common of these events are shown
in Table 2. Related TEAEs occurring in >4 % of patients
were (for CT-P13) abnormal liver function test (n = 16
(12.5 %)), upper respiratory tract infection (n = 12 (9.4 %)),
infusion-related reaction (n = 11 (8.6 %)) and latent TB (9
(7.0 %)), and (for RP) abnormal liver function test (n = 15
(12.3 %)), infusion-related reaction (n = 15 (12.3 %)), upper
respiratory tract infection (n = 8 (6.6 %)) and latent TB (6
(4.9 %)). Infusion-related reactions affected more ADA-
positive than ADA-negative patients in both treatment
groups (CT-P13: 6/44 (13.6 %) versus 5/84 (6.0 %); RP: 11/
39 (28.2 %) versus 4/83 (4.8 %)).
Two cases of active TB were reported in the CT-P13
group and one case was reported in the RP group. A sin-
gle case of malignancy, which was considered to be un-
related to treatment, was reported in the CT-P13 group
(basal cell carcinoma). The onset date of this event was
unknown, but was believed to have started 2 years previ-
ously, based on the medical history of the patient (mel-
anocyte nevus). Treatment for the event was excision of
a skin nodule of the nose. The event was considered to
have recovered/resolved according to the investigator.
The proportion of patients who experienced at least
one serious AE (SAE) was similar between the CT-P13
and RP groups (n = 10 (7.8 %) and 8 (6.6 %), respect-
ively), as was the proportion who had an SAE considered
related to treatment (n = 4 (3.1 %) and 5 (4.1 %); see
Additional file 1 for details of treatment-related SAEs).
The number of patients with at least one TEAE leading
to discontinuation was comparable between the CT-P13
Fig. 2 Proportion of patients with an ASAS20 response, ASAS40 response and ASAS PR* up to week 54 by treatment in the a ITT population
(MEX approach) and b ITT population (LOCF approach). “n = numbers” in the bar represent the denominator of patients assessed at each time
point. *PR was defined as a value of <20 on a 0–100 scale in each of the following four domains: patient global assessment, pain, function, and
inflammation. ASAS Assessment of Spondylo Arthritis international Society (ASAS20 and ASAS40, 20 % and 40 % response according to the ASAS
International Working Group criteria for improvement), ITT intention-to-treat, LOCF last observation carried forward, MEX missing equals excluded,
PR partial remission, RP reference product (i.e. reference infliximab)
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and RP groups (n = 11 (8.6 %) and 9 (7.4 %), respect-
ively). Of these, 9 (7.0 %) and 7 (5.7 %) were considered
to be related to CT-P13 and RP, respectively. Overall,
treatment-related events leading to discontinuation of
more than one patient were TB in two patients from the
CT-P13 group and one in the RP group, two abnormal
liver function tests (one in each group), and infusion-
related reactions in one patient from the CT-P13 group
and five from the RP group. Two deaths occurred during
the study, one in each treatment group. Both were due
to car accidents and were considered not related to
study treatment.
Discussion
PLANETAS was a multinational, randomized, double-
blind biosimilar study that evaluated the equivalence of
PK and comparability of efficacy and safety between CT-
P13 and RP up to 54 weeks in patients with active AS.
Similar clinical efficacy was observed between CT-P13
and RP up to week 54. ASAS responses at weeks 30 and
Fig. 3 Mean a BASDAI, b BASFI, c SF-36 Physical Component Summary, d SF-36 Mental Component Summary and e BASMI scores up to week 54
by treatment. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing
Spondylitis Metrology Index, RP reference product (i.e. reference infliximab), SF-36 Short Form (36) Health Survey, SE standard error
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54, respectively, were comparable in the two treatment
groups. PROs—including mean BASDAI, BASFI and SF-
36 scores—and other efficacy endpoints such as BASMI
score and chest expansion were also similar in both
treatment groups up to week 54. The similarity in PROs
is notable because, unlike the other efficacy endpoints
employed in the study, these are patient-led evaluations.
Thirty-week efficacy data in PLANETAS were compar-
able to 24-week data from a pivotal placebo-controlled
clinical study of RP in AS (ASSERT) [2, 13]. Analo-
gously, the efficacy data seen here for CT-P13 at week
54 are in line with findings previously reported for RP in
different clinical trials with a similar duration [15–17].
For example, in the current analysis, the ASAS20 re-
sponses and improvement of BASDAI and BASFI scores
with CT-P13 at 54 weeks were 67 %, 3.1 and 2.9, re-
spectively. Similar improvements in these measurements
were also observed at weeks 48–58 in historical studies
with RP (ASAS20 at week 58 = 75 %; BASDAI from 6.6
at week 0 to 2.4 at week 54; BASFI from 6.1 at baseline
to 4.4 at week 48) [15–17]. While there are inherent
limitations associated with comparing across trials due to
differences in patient populations and methods, it is re-
assuring that the data for CT-P13 are generally in line
with historical observations for RP. Long-term efficacy
equivalence of CT-P13 and RP has also been established
in a 54-week analysis of the PLANETRA study in rheuma-
toid arthritis (RA). An American College of Rheumatology
(ACR)20 response was achieved in a highly similar pro-
portion of patients treated with CT-P13 and RP [18].
The long-term PK profiles (Cmax and Cmin) of CT-P13
and RP were similar to each other in the current study
through to week 54. The Cmax data reported here are
consistent with PLANETAS data reported at 30 weeks
and those of studies adopting a similar RP dosing pat-
tern in Crohn’s disease [13, 19]. Similarity of PK was also
observed between CT-P13 and RP in patients with RA
in the PLANETRA study [12, 18].
CT-P13 was well tolerated up to week 54, with a safety
profile comparable to that of RP. As previously reported
at week 30 for PLANETAS [13], there was no notable
difference between study arms in the incidence of AEs,
SAEs, infections and infusion-related reactions; this
trend continued up to week 54. The safety profile ob-
served with CT-P13 in the current study is also generally
aligned with the safety profile of RP in historical studies
involving patients with AS and RA [1, 2, 15–17, 20–29].
One treatment-unrelated case of basal cell carcinoma
was reported with CT-P13. It is believed that the malig-
nancy started 2 years prior to study participation. Fol-
lowing appropriate treatment (excision), the event was
considered to have resolved.
It is well documented that development of ADAs
against infliximab is associated with decreased clinical
response and drug serum concentration [13, 30–32]. We
also observed lower ASAS20 response rates and lower
Cmax values at week 54, as well as a higher incidence of
infusion-related reactions in ADA-positive compared
with ADA-negative patients. These ADA effects were
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Fig. 4 Mean (SD) serum PK parameters of CT-P13 and RP (PK population).
Note: values below the LLOQ have been set equal to the LLOQ. LLOQ
lower limit of quantification, PK pharmacokinetics, RP reference product
(i.e. reference infliximab), SD standard deviation
Fig. 5 Primary PK parameters (Cmax,ss and AUCτ) by ADA titer level at week 30 (PK population). Note: titer levels were defined as low, medium
and high titer based on tertile grouping of the data. ADA anti-drug antibodies, AUCτ area under the concentration time curve over the dosing
interval, at steady state between week 22 and week 30, Cmax,ss the observed maximum serum concentration at steady state between week 22
and week 30, PK pharmacokinetics, RP reference product (i.e. reference infliximab)
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analysis of PK parameters with respect to ADA levels
found a trend for both AUCτ, and Cmax,ss to be lower
with increasing ADA titer level, although a formal
statistical inference was not made due to a limited
statistical power.
Further extensions of the current study and the PLA-
NETRA study were conducted to examine the efficacy
and safety of switching treatment from RP to CT-P13 in
patients with AS and RA, respectively. Additionally, a
formal randomized double-blind ‘switching’ clinical trial
is currently progressing in Norway. This trial (‘NOR-
SWITCH’; ClinicalTrials.gov identifier: NCT02148640)
is comparing the safety and efficacy of switching from
RP to CT-P13 versus continued treatment with RP in
several indications, including RA. Data from the PLA-
NETAS/PLANETRA extensions and NOR-SWITCH will
provide further evidence on the ability to switch from
RP to CT-P13.
The main limitation of this analysis is that PLANE-
TAS was primarily designed to compare the PK pro-
files of CT-P13 and RP at 30 weeks. While
prospectively planned, the longer-term efficacy, safety
and PK data presented here are from a secondary
analysis of the study.
Conclusions
This multinational, randomized, biosimilar study in pa-
tients with active AS demonstrated that CT-P13 and RP
have highly comparable efficacy, safety, immunogenicity
and PK profiles up to week 54. Together with the find-
ings from the PLANETRA study in patients with RA,
these data further demonstrate the similarity between
CT-P13 and RP in diverse clinical settings.
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